New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new ...

Some patients may switch to copycats of another GLP-1 drug, semaglutide, the main ingredient in the type 2 diabetes drug Ozempic and the weight loss drug Wegovy. Semaglutide remains on the FDA’s ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on ...

Whenever a new year begins, most of us strive to make some resolutions such as going to the gym, drinking less (aka, Sober ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from cancer and type 2 diabetes to asthma.

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...